In terms of effective field theory and mixed propagator approach, we show that there is a larger hidden effect of isospin breaking in ρ 0 → π 0 γ decay due to an ω exchange, ρ 0 → ω → π 0 γ. The branching ratio is predicted as B(ρ 0 → π 0 γ) = (11.67±2.0)×10 −4 , which is much larger than Partcile Data Group's datum (6.8±1.7)×10 −4 and one of charged mode, B(ρ ± → π ± γ) = (4.5±0.5)×10 −4 .
This network meta-analysis is adopted in order to compare the toxicity of different chemotherapy regimens in the treatment of advanced/metastatic pancreatic cancer (PC). Randomized controlled trials (RCTs) about different chemotherapy regimens for advanced/metastatic PC were included in this network meta-analysis using Cochrane Library and PubMed electronic databases. The network meta-analysis was performed to combine direct and indirect evidence in order to calculate the odd ratios (OR) and draw a surface under the cumulative ranking (SUCRA) curve. A total of 19 RCTs were enrolled in this network meta-analysis including 12 chemotherapy regimens (Gemcitabine, Gemcitabine + S-1 [tegafur], Gemcitabine + nab-paclitaxel, Gemcitabine + Capecitabine, Gemcitabine + Cisplatin, FOLFIRINOX [oxaliplatin + irinotecan + fluorouracil + leucovorin], Gemcitabine + oxaliplatin, Gemcitabine + irinotecan, Gemcitabine + Exatecan, Gemcitabine + pemetrexed, Gemcitabine + 5-FU, S-1). The incidence of anemia of Gemcitabine + Capecitabine regimen was higher compared with Gemcitabine regimen, Gemcitabine + pemetrexed regimen exhibited the highest incidence rates of anemia and neutropenia; while Gemcitabine + S-1, Gemcitabine + Cisplatin and FOLFIRINOX regimens exhibited the highest incidence rates of neutropenia. However, S-1 regimen exhibited lower incidence rates of leukopenia and thrombocytopenia. Moreover, the incidence rates of nausea/vomiting and rash of Gemcitabine + S-1 regimen were higher compared with Gemcitabine regimen, while Gemcitabine + Cisplatin regimen had the highest incidence rate of nausea/vomiting. This study demonstrated that the hematologic toxicity of S-1 regimen was the lowest, while Gemcitabine regimen exhibited the lowest incidence rate of non-hematologic toxicity, providing guidance for the treatment of advanced/metastatic PC.
Mixed Propagator (MP) approach to ρ − ω mixing is discussed. It is found that under the poleapproximation assumption the results of MP approach is not compatible both with the effective Lagrangian theory and with the experiment measurement criterion. To overcome these inconsistent, we propose a new MP approach in which the physical states of ρ and ω are determined by the requirement of experimental measurement to meson resonance. In terms of this new MP approach, the EM pion form factor Fπ and form factors of ρ 0 → π 0 γ and of ω → π 0 γ are derived. The results of Fπ are in good agreement with data. The form factor of ρ 0 → π 0 γ exhibits a hidden charge-asymmetry enhancement effect which agree with the prediction of the effective Lagrangian theory.14.40.Cs,13.25.Jx,12.40.Vv,13.40.Hq ρ 0 − ω mixing (or ρ 0 − ω interference, or interference between overlapping resonances, or charge asymmetry caused by ρ − ω mixing and so on) has attracted much interest during past four decades. Since 1961 [1], there is a great deal of works on this subject in the literature (see, for example, review articles [2,3] and the references within). Recently, we used model-independent effective Lagrangian (eff-L) approach to discuss ρ− and ω− anomaly-like processes of ρ 0 → π 0 γ, and of ω → π 0 γ [4]. It has been found that there exist a hidden charge-asymmetry enhancement effect to ρ 0 → π 0 γ due to ρ 0 − ω mixing. Namely, we have (by using the notations in ref [4])where the subscript 'eff-L' means the results obtained by in the effective Lagrangian approach. Due to Γ ω << Γ ρ , we haveThis reflects an unusual charge asymmetry enhancement effect for ρ → πγ. As addressed in [4], this hidden effect has already been implied by experiment [5].On the other hand, There is a well-known quantum mechanics method to deal with the ρ − ω mixing problem: the approach of mixed propagator with pole approximation (shortly, we will call it as pole-Mixed-Propagator approach, or pole-MP approach) [2,3]. This approach was developed even before discovery of QCD. A question arisen here what are results for ρ 0 → π 0 γ and ω → π 0 γ in pole-MP approach? The vector meson propagator is given by (Renard representation) †
The decay K L → γνν is investigated beyond the standard model. Interestingly, the upper limit of the CP -conserving and CP -violating branching ratios of the decay, induced from the possible extensions of the standard model, would be larger than the corresponding branching ratios given in the standard model respectively, and it is expected that the CP -violating part could be enhanced.
We study the CP -violating asymmetry in nonleptonic decay Λ → pπ. By employing the Skyrme model to calculate this decay amplitude contributed by the gluonic diploe operator, we find a possible large CP -violating asymmetry could be expected, which is consistent with the previous study.11.30. Er, 12.60.Jv, 13.30.Eg, 14.20.Jn Typeset using REVT E X 1 CP -violating asymmetry in Λ → pπ in the Skyrme model where α is hyperon decays parameter of Λ 0 − → pπ − andᾱ corresponds toΛ 0 − →pπ + , δ s = 6 o and δ p = −1.1 o are the final state πN strong interaction phases for S and P wave amplitudes with ∆I = 1/2 respectively [5], and φ s,p are the corresponding CP −violating weak phases. The standard model prediction for A(Λ 0 − ) is around 3 × 10 −5 , and the recent study in Ref. [2] showsA model independent study of new CP −violating interactions has shown that A(Λ 0 − ) could be larger than that predicted within the standard model [6]. An example of an operator is precisely the gluonic dipole operator [1,6], in which A(Λ 0 − ) would be enhanced and could reach around O(10 −3 ) [1]. *
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.